Keywords: dyax/genzyme, dx-88, succeeds, ph, ii, trial, positive
Dyax/Genzyme's DX-88 succeeds in Ph II trial
Article | 21 June 2004
Positive preliminary results have been released from a double-blind, placebo-controlled Phase II trial evaluating Dyax Corp's DX-88 as a potential ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
